London
· Delayed Price · Currency is GBP · Price in GBXPoolbeg Pharma Company Description
Poolbeg Pharma PLC operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom.
It develops POLB 001, which is in phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome and severe influenza.
The company is also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; influenza and respiratory syncytial virus AI programme; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.
In addition, it has a license to encapsulation technology for oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut.
Further, the company is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates.
Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Jeremy Skillington |
Contact Details
Address: 40 Bank Street London, E14 5NR United Kingdom | |
| Phone | 44 20 7183 1499 |
| Website | poolbegpharma.com |
Stock Details
| Ticker Symbol | POLB |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00BKPG7Z60 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeremy Skillington | Chief Executive Officer |
| Ian O'Connell | Chief Financial Officer |
| Carol Dalton | Head of Investor Relations |